TriSalus reports Q3 2026 revenue, trims full-year guidance range
TriSalus posted $12.9 million in third-quarter revenue and narrowed 2026 revenue guidance to $46 million to $48 million as new Medicare reimbursement rules take effect in 2027.
TriSalus Life Sciences reported third-quarter 2026 results on November 10, 2026, alongside an operational update covering regulatory, reimbursement and trial developments.
During the quarter, the company said it received FDA clearance for TriNav Advance, which enables Pressure-Enabled Drug Delivery to small distal vessels through the microcatheter of the physician's choice1. CEO Mary Szela said this clearance allows the company to address the full range of vessels encountered in liver embolization procedures going forward1.
On reimbursement, CMS finalized changes affecting TriSalus procedures starting in 2027. In the hospital outpatient rule, CMS reassigned HCPCS code C8004 to a new payment category aligned with C9797, which will raise the national Medicare payment rate for procedures billed under that code from approximately $11,794 to approximately $20,910, effective January 1, 2027.1 Separately, CMS's 2027 Physician Fee Schedule final rule established national payment for HCPCS code G0577 covering vascular embolization with a pressure-generating catheter in office-based labs, with total national office payment of about $13,800 per procedure effective January 1, 2027, extending reimbursement for PEDD.1
On the clinical side, TriSalus said it reached the enrollment cutoff needed for an interim analysis of the PROTECT registry studying thyroid artery embolization, and remains on track to report the first multi-center U.S. data on that procedure in the first quarter of 2027.1 The company also described its nelitolimod program as nearing completion of data from several Phase 1 trials, after which it intends to pursue partnership discussions for further development.
Financially, quarterly TriNav system revenue rose 11.3% year over year to $12.9 million1, and the company revised its full-year 2026 revenue guidance to a range of $46 million to $48 million, representing roughly 2% to 6% growth versus 2025.1 Cash and cash equivalents stood at $41.1 million as of September 30, 2026, after a $46.0 million equity raise completed in the first quarter.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.